Global Guillain-Barre Syndrome Drugs

Guillain-Barre Syndrome Drugs Comprehensive Study by Type (Coversin, Immune Globulin, Others), Application (Clinic, Hospital, Others), Forms (Tablets, Injection), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others) Players and Region - Global Market Outlook to 2030

Guillain-Barre Syndrome Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Guillain-Barre Syndrome Drugs Market Overview:
Guillain Barré syndrome drugs are used to treatment of Guillain Barré syndrome diseases. Guillain Barré syndrome is an acute immune-mediated polyneuropathy where the immune system is triggered into attacking the myelin sheath surrounding nerves, leading to progressive, fairly symmetric muscle weakness accompanied by absent or depressed deep tendon reflexes. Patients usually present a few days to a week after onset of symptoms. The weakness can vary from mild difficulty with walking to nearly complete paralysis of all extremities, facial, respiratory, and bulbar muscles. As per latest study released by AMA Research, the Global Guillain-Barre Syndrome Drugs market is expected to see growth rate of 6.6%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Technological advancement in Guillain-Barre Syndrome Drugs

Market Growth Drivers:
Increasing number of patients of Guillain-Barré syndrome is driving the global Guillain-Barre Syndrome Drugs market. Nearly 6,000 patients admitted to US hospitals with a primary diagnosis of GBS every year.

Challenges:
Increasing the GBS and Geriatric Population

Restraints:
Guillain-Barré syndrome can be difficult to diagnose in its earliest stages

Opportunities:
Increasing Investment in Research and Development by Various Manufacturers

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Akari Therapeutics Plc (United States), Annexon Inc (United States), CuraVac Inc (United States), Hansa Medical AB (Sweden), Vitality Biopharma Inc (United States), Grifols, S.A. (Spain), CSL Behring (United States), Shire Plc (United States), Octapharma AG (Switzerland) and Takeda Pharmaceuticals (Japan). The Players having a strong hold in the market are Akari Therapeutics Plc, Annexon Inc, CuraVac Inc, and Hansa Medical AB. Additionally, following companies can also be profiled that are part of our coverage like China Biologic Products Holdings (China) and Biotest (Germany). Analyst at AMA Research see United States Players to retain maximum share of Global Guillain-Barre Syndrome Drugs market by 2030. Considering Market by Forms, the sub-segment i.e. Tablets will boost the Guillain-Barre Syndrome Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Guillain-Barre Syndrome Drugs market.

Latest Market Insights:
In March 2023,Hansa Biopharma announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barr Syndrome (GBS). Top-line data is expected to be shared during the second half of 2023. The phase 2 study in GBS is an open-label, single arm, multi-center study across the UK, France, and the Netherlands evaluating the safety, tolerability,

In October 2023, Annexin, Inc. a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the European Medicines Agency (EMA) granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome (GBS)

What Can be Explored with the Guillain-Barre Syndrome Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Guillain-Barre Syndrome Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Guillain-Barre Syndrome Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Guillain-Barre Syndrome Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Guillain-Barre Syndrome Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Raw Material Suppliers and Distributors, Guillain-Barre Syndrome Drugs Manufacturers, Government and Research Organizations, Associations and Industrial Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Coversin
  • Immune Globulin
  • Others
By Application
  • Clinic
  • Hospital
  • Others
By Forms
  • Tablets
  • Injection

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing number of patients of Guillain-Barré syndrome is driving the global Guillain-Barre Syndrome Drugs market. Nearly 6,000 patients admitted to US hospitals with a primary diagnosis of GBS every year.
    • 3.3. Market Challenges
      • 3.3.1. Increasing the GBS and Geriatric Population
    • 3.4. Market Trends
      • 3.4.1. Technological advancement in Guillain-Barre Syndrome Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Guillain-Barre Syndrome Drugs, by Type, Application, Forms, Distribution Channel and Region (value and volume ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Guillain-Barre Syndrome Drugs (Value)
      • 5.2.1. Global Guillain-Barre Syndrome Drugs by: Type (Value)
        • 5.2.1.1. Coversin
        • 5.2.1.2. Immune Globulin
        • 5.2.1.3. Others
      • 5.2.2. Global Guillain-Barre Syndrome Drugs by: Application (Value)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Others
      • 5.2.3. Global Guillain-Barre Syndrome Drugs by: Forms (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Injection
      • 5.2.4. Global Guillain-Barre Syndrome Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Guillain-Barre Syndrome Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Guillain-Barre Syndrome Drugs (Volume)
      • 5.3.1. Global Guillain-Barre Syndrome Drugs by: Type (Volume)
        • 5.3.1.1. Coversin
        • 5.3.1.2. Immune Globulin
        • 5.3.1.3. Others
      • 5.3.2. Global Guillain-Barre Syndrome Drugs by: Application (Volume)
        • 5.3.2.1. Clinic
        • 5.3.2.2. Hospital
        • 5.3.2.3. Others
      • 5.3.3. Global Guillain-Barre Syndrome Drugs by: Forms (Volume)
        • 5.3.3.1. Tablets
        • 5.3.3.2. Injection
      • 5.3.4. Global Guillain-Barre Syndrome Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online
        • 5.3.4.4. Others
      • 5.3.5. Global Guillain-Barre Syndrome Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
  • 6. Guillain-Barre Syndrome Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Akari Therapeutics Plc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Annexon Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CuraVac Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hansa Medical AB (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vitality Biopharma Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Grifols, S.A. (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CSL Behring (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shire Plc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Octapharma AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takeda Pharmaceuticals (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Guillain-Barre Syndrome Drugs Sale, by Type, Application, Forms, Distribution Channel and Region (value and volume ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Guillain-Barre Syndrome Drugs (Value)
      • 7.2.1. Global Guillain-Barre Syndrome Drugs by: Type (Value)
        • 7.2.1.1. Coversin
        • 7.2.1.2. Immune Globulin
        • 7.2.1.3. Others
      • 7.2.2. Global Guillain-Barre Syndrome Drugs by: Application (Value)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Others
      • 7.2.3. Global Guillain-Barre Syndrome Drugs by: Forms (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Injection
      • 7.2.4. Global Guillain-Barre Syndrome Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Guillain-Barre Syndrome Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Guillain-Barre Syndrome Drugs (Volume)
      • 7.3.1. Global Guillain-Barre Syndrome Drugs by: Type (Volume)
        • 7.3.1.1. Coversin
        • 7.3.1.2. Immune Globulin
        • 7.3.1.3. Others
      • 7.3.2. Global Guillain-Barre Syndrome Drugs by: Application (Volume)
        • 7.3.2.1. Clinic
        • 7.3.2.2. Hospital
        • 7.3.2.3. Others
      • 7.3.3. Global Guillain-Barre Syndrome Drugs by: Forms (Volume)
        • 7.3.3.1. Tablets
        • 7.3.3.2. Injection
      • 7.3.4. Global Guillain-Barre Syndrome Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online
        • 7.3.4.4. Others
      • 7.3.5. Global Guillain-Barre Syndrome Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Guillain-Barre Syndrome Drugs: by Type(USD Million)
  • Table 2. Guillain-Barre Syndrome Drugs Coversin , by Region USD Million (2018-2023)
  • Table 3. Guillain-Barre Syndrome Drugs Immune Globulin , by Region USD Million (2018-2023)
  • Table 4. Guillain-Barre Syndrome Drugs Others , by Region USD Million (2018-2023)
  • Table 5. Guillain-Barre Syndrome Drugs: by Application(USD Million)
  • Table 6. Guillain-Barre Syndrome Drugs Clinic , by Region USD Million (2018-2023)
  • Table 7. Guillain-Barre Syndrome Drugs Hospital , by Region USD Million (2018-2023)
  • Table 8. Guillain-Barre Syndrome Drugs Others , by Region USD Million (2018-2023)
  • Table 9. Guillain-Barre Syndrome Drugs: by Forms(USD Million)
  • Table 10. Guillain-Barre Syndrome Drugs Tablets , by Region USD Million (2018-2023)
  • Table 11. Guillain-Barre Syndrome Drugs Injection , by Region USD Million (2018-2023)
  • Table 12. Guillain-Barre Syndrome Drugs: by Distribution Channel(USD Million)
  • Table 13. Guillain-Barre Syndrome Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Guillain-Barre Syndrome Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 15. Guillain-Barre Syndrome Drugs Online , by Region USD Million (2018-2023)
  • Table 16. Guillain-Barre Syndrome Drugs Others , by Region USD Million (2018-2023)
  • Table 17. South America Guillain-Barre Syndrome Drugs, by Country USD Million (2018-2023)
  • Table 18. South America Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 19. South America Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 20. South America Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 21. South America Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 23. Brazil Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 24. Brazil Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 25. Brazil Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 27. Argentina Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 28. Argentina Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 29. Argentina Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 30. Rest of South America Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 33. Rest of South America Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 34. Asia Pacific Guillain-Barre Syndrome Drugs, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 38. Asia Pacific Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 39. China Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 40. China Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 41. China Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 42. China Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 43. Japan Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 44. Japan Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 45. Japan Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 46. Japan Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. India Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 48. India Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 49. India Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 50. India Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 51. South Korea Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 52. South Korea Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 53. South Korea Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 54. South Korea Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 55. Taiwan Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 56. Taiwan Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 57. Taiwan Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 58. Taiwan Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 60. Australia Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 61. Australia Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 62. Australia Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 67. Europe Guillain-Barre Syndrome Drugs, by Country USD Million (2018-2023)
  • Table 68. Europe Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 69. Europe Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 70. Europe Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 71. Europe Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 73. Germany Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 74. Germany Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 75. Germany Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 77. France Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 78. France Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 79. France Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 81. Italy Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 82. Italy Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 83. Italy Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 87. United Kingdom Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 88. Netherlands Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 89. Netherlands Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 90. Netherlands Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 91. Netherlands Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. Rest of Europe Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 95. Rest of Europe Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 96. MEA Guillain-Barre Syndrome Drugs, by Country USD Million (2018-2023)
  • Table 97. MEA Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 98. MEA Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 99. MEA Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 100. MEA Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 101. Middle East Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 102. Middle East Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 103. Middle East Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 104. Middle East Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 105. Africa Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 106. Africa Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 107. Africa Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 108. Africa Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 109. North America Guillain-Barre Syndrome Drugs, by Country USD Million (2018-2023)
  • Table 110. North America Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 111. North America Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 112. North America Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 113. North America Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 114. United States Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 115. United States Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 116. United States Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 117. United States Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 118. Canada Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 119. Canada Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 120. Canada Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 121. Canada Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 122. Mexico Guillain-Barre Syndrome Drugs, by Type USD Million (2018-2023)
  • Table 123. Mexico Guillain-Barre Syndrome Drugs, by Application USD Million (2018-2023)
  • Table 124. Mexico Guillain-Barre Syndrome Drugs, by Forms USD Million (2018-2023)
  • Table 125. Mexico Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 126. Guillain-Barre Syndrome Drugs Sales: by Type(K Units)
  • Table 127. Guillain-Barre Syndrome Drugs Sales Coversin , by Region K Units (2018-2023)
  • Table 128. Guillain-Barre Syndrome Drugs Sales Immune Globulin , by Region K Units (2018-2023)
  • Table 129. Guillain-Barre Syndrome Drugs Sales Others , by Region K Units (2018-2023)
  • Table 130. Guillain-Barre Syndrome Drugs Sales: by Application(K Units)
  • Table 131. Guillain-Barre Syndrome Drugs Sales Clinic , by Region K Units (2018-2023)
  • Table 132. Guillain-Barre Syndrome Drugs Sales Hospital , by Region K Units (2018-2023)
  • Table 133. Guillain-Barre Syndrome Drugs Sales Others , by Region K Units (2018-2023)
  • Table 134. Guillain-Barre Syndrome Drugs Sales: by Forms(K Units)
  • Table 135. Guillain-Barre Syndrome Drugs Sales Tablets , by Region K Units (2018-2023)
  • Table 136. Guillain-Barre Syndrome Drugs Sales Injection , by Region K Units (2018-2023)
  • Table 137. Guillain-Barre Syndrome Drugs Sales: by Distribution Channel(K Units)
  • Table 138. Guillain-Barre Syndrome Drugs Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 139. Guillain-Barre Syndrome Drugs Sales Retail Pharmacies , by Region K Units (2018-2023)
  • Table 140. Guillain-Barre Syndrome Drugs Sales Online , by Region K Units (2018-2023)
  • Table 141. Guillain-Barre Syndrome Drugs Sales Others , by Region K Units (2018-2023)
  • Table 142. South America Guillain-Barre Syndrome Drugs Sales, by Country K Units (2018-2023)
  • Table 143. South America Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 144. South America Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 145. South America Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 146. South America Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 147. Brazil Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 148. Brazil Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 149. Brazil Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 150. Brazil Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 151. Argentina Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 152. Argentina Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 153. Argentina Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 154. Argentina Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 155. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 156. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 157. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 158. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 159. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Country K Units (2018-2023)
  • Table 160. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 161. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 162. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 163. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 164. China Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 165. China Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 166. China Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 167. China Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 168. Japan Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 169. Japan Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 170. Japan Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 171. Japan Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 172. India Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 173. India Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 174. India Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 175. India Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 176. South Korea Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 177. South Korea Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 178. South Korea Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 179. South Korea Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 180. Taiwan Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 181. Taiwan Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 182. Taiwan Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 183. Taiwan Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 184. Australia Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 185. Australia Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 186. Australia Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 187. Australia Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 188. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 189. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 190. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 191. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 192. Europe Guillain-Barre Syndrome Drugs Sales, by Country K Units (2018-2023)
  • Table 193. Europe Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 194. Europe Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 195. Europe Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 196. Europe Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 197. Germany Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 198. Germany Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 199. Germany Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 200. Germany Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 201. France Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 202. France Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 203. France Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 204. France Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 205. Italy Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 206. Italy Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 207. Italy Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 208. Italy Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 209. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 210. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 211. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 212. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 213. Netherlands Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 214. Netherlands Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 215. Netherlands Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 216. Netherlands Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 217. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 218. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 219. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 220. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 221. MEA Guillain-Barre Syndrome Drugs Sales, by Country K Units (2018-2023)
  • Table 222. MEA Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 223. MEA Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 224. MEA Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 225. MEA Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 226. Middle East Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 227. Middle East Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 228. Middle East Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 229. Middle East Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 230. Africa Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 231. Africa Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 232. Africa Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 233. Africa Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 234. North America Guillain-Barre Syndrome Drugs Sales, by Country K Units (2018-2023)
  • Table 235. North America Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 236. North America Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 237. North America Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 238. North America Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 239. United States Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 240. United States Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 241. United States Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 242. United States Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 243. Canada Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 244. Canada Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 245. Canada Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 246. Canada Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 247. Mexico Guillain-Barre Syndrome Drugs Sales, by Type K Units (2018-2023)
  • Table 248. Mexico Guillain-Barre Syndrome Drugs Sales, by Application K Units (2018-2023)
  • Table 249. Mexico Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2018-2023)
  • Table 250. Mexico Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2018-2023)
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Guillain-Barre Syndrome Drugs: by Type(USD Million)
  • Table 262. Guillain-Barre Syndrome Drugs Coversin , by Region USD Million (2025-2030)
  • Table 263. Guillain-Barre Syndrome Drugs Immune Globulin , by Region USD Million (2025-2030)
  • Table 264. Guillain-Barre Syndrome Drugs Others , by Region USD Million (2025-2030)
  • Table 265. Guillain-Barre Syndrome Drugs: by Application(USD Million)
  • Table 266. Guillain-Barre Syndrome Drugs Clinic , by Region USD Million (2025-2030)
  • Table 267. Guillain-Barre Syndrome Drugs Hospital , by Region USD Million (2025-2030)
  • Table 268. Guillain-Barre Syndrome Drugs Others , by Region USD Million (2025-2030)
  • Table 269. Guillain-Barre Syndrome Drugs: by Forms(USD Million)
  • Table 270. Guillain-Barre Syndrome Drugs Tablets , by Region USD Million (2025-2030)
  • Table 271. Guillain-Barre Syndrome Drugs Injection , by Region USD Million (2025-2030)
  • Table 272. Guillain-Barre Syndrome Drugs: by Distribution Channel(USD Million)
  • Table 273. Guillain-Barre Syndrome Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 274. Guillain-Barre Syndrome Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 275. Guillain-Barre Syndrome Drugs Online , by Region USD Million (2025-2030)
  • Table 276. Guillain-Barre Syndrome Drugs Others , by Region USD Million (2025-2030)
  • Table 277. South America Guillain-Barre Syndrome Drugs, by Country USD Million (2025-2030)
  • Table 278. South America Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 279. South America Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 280. South America Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 281. South America Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 282. Brazil Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 283. Brazil Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 284. Brazil Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 285. Brazil Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 286. Argentina Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 287. Argentina Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 288. Argentina Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 289. Argentina Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 290. Rest of South America Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 291. Rest of South America Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 292. Rest of South America Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 293. Rest of South America Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 294. Asia Pacific Guillain-Barre Syndrome Drugs, by Country USD Million (2025-2030)
  • Table 295. Asia Pacific Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 296. Asia Pacific Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 297. Asia Pacific Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 298. Asia Pacific Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 299. China Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 300. China Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 301. China Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 302. China Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 303. Japan Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 304. Japan Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 305. Japan Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 306. Japan Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 307. India Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 308. India Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 309. India Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 310. India Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 311. South Korea Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 312. South Korea Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 313. South Korea Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 314. South Korea Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 315. Taiwan Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 316. Taiwan Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 317. Taiwan Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 318. Taiwan Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 319. Australia Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 320. Australia Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 321. Australia Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 322. Australia Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 326. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 327. Europe Guillain-Barre Syndrome Drugs, by Country USD Million (2025-2030)
  • Table 328. Europe Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 329. Europe Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 330. Europe Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 331. Europe Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 332. Germany Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 333. Germany Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 334. Germany Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 335. Germany Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 336. France Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 337. France Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 338. France Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 339. France Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 340. Italy Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 341. Italy Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 342. Italy Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 343. Italy Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 344. United Kingdom Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 345. United Kingdom Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 346. United Kingdom Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 347. United Kingdom Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 348. Netherlands Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 349. Netherlands Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 350. Netherlands Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 351. Netherlands Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 352. Rest of Europe Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 353. Rest of Europe Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 354. Rest of Europe Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 355. Rest of Europe Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 356. MEA Guillain-Barre Syndrome Drugs, by Country USD Million (2025-2030)
  • Table 357. MEA Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 358. MEA Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 359. MEA Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 360. MEA Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 361. Middle East Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 362. Middle East Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 363. Middle East Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 364. Middle East Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 365. Africa Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 366. Africa Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 367. Africa Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 368. Africa Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 369. North America Guillain-Barre Syndrome Drugs, by Country USD Million (2025-2030)
  • Table 370. North America Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 371. North America Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 372. North America Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 373. North America Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 374. United States Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 375. United States Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 376. United States Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 377. United States Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 378. Canada Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 379. Canada Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 380. Canada Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 381. Canada Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 382. Mexico Guillain-Barre Syndrome Drugs, by Type USD Million (2025-2030)
  • Table 383. Mexico Guillain-Barre Syndrome Drugs, by Application USD Million (2025-2030)
  • Table 384. Mexico Guillain-Barre Syndrome Drugs, by Forms USD Million (2025-2030)
  • Table 385. Mexico Guillain-Barre Syndrome Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 386. Guillain-Barre Syndrome Drugs Sales: by Type(K Units)
  • Table 387. Guillain-Barre Syndrome Drugs Sales Coversin , by Region K Units (2025-2030)
  • Table 388. Guillain-Barre Syndrome Drugs Sales Immune Globulin , by Region K Units (2025-2030)
  • Table 389. Guillain-Barre Syndrome Drugs Sales Others , by Region K Units (2025-2030)
  • Table 390. Guillain-Barre Syndrome Drugs Sales: by Application(K Units)
  • Table 391. Guillain-Barre Syndrome Drugs Sales Clinic , by Region K Units (2025-2030)
  • Table 392. Guillain-Barre Syndrome Drugs Sales Hospital , by Region K Units (2025-2030)
  • Table 393. Guillain-Barre Syndrome Drugs Sales Others , by Region K Units (2025-2030)
  • Table 394. Guillain-Barre Syndrome Drugs Sales: by Forms(K Units)
  • Table 395. Guillain-Barre Syndrome Drugs Sales Tablets , by Region K Units (2025-2030)
  • Table 396. Guillain-Barre Syndrome Drugs Sales Injection , by Region K Units (2025-2030)
  • Table 397. Guillain-Barre Syndrome Drugs Sales: by Distribution Channel(K Units)
  • Table 398. Guillain-Barre Syndrome Drugs Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 399. Guillain-Barre Syndrome Drugs Sales Retail Pharmacies , by Region K Units (2025-2030)
  • Table 400. Guillain-Barre Syndrome Drugs Sales Online , by Region K Units (2025-2030)
  • Table 401. Guillain-Barre Syndrome Drugs Sales Others , by Region K Units (2025-2030)
  • Table 402. South America Guillain-Barre Syndrome Drugs Sales, by Country K Units (2025-2030)
  • Table 403. South America Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 404. South America Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 405. South America Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 406. South America Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 407. Brazil Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 408. Brazil Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 409. Brazil Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 410. Brazil Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 411. Argentina Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 412. Argentina Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 413. Argentina Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 414. Argentina Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 415. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 416. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 417. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 418. Rest of South America Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 419. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Country K Units (2025-2030)
  • Table 420. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 421. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 422. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 423. Asia Pacific Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 424. China Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 425. China Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 426. China Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 427. China Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 428. Japan Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 429. Japan Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 430. Japan Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 431. Japan Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 432. India Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 433. India Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 434. India Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 435. India Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 436. South Korea Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 437. South Korea Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 438. South Korea Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 439. South Korea Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 440. Taiwan Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 441. Taiwan Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 442. Taiwan Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 443. Taiwan Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 444. Australia Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 445. Australia Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 446. Australia Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 447. Australia Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 448. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 449. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 450. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 451. Rest of Asia-Pacific Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 452. Europe Guillain-Barre Syndrome Drugs Sales, by Country K Units (2025-2030)
  • Table 453. Europe Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 454. Europe Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 455. Europe Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 456. Europe Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 457. Germany Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 458. Germany Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 459. Germany Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 460. Germany Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 461. France Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 462. France Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 463. France Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 464. France Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 465. Italy Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 466. Italy Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 467. Italy Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 468. Italy Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 469. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 470. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 471. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 472. United Kingdom Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 473. Netherlands Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 474. Netherlands Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 475. Netherlands Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 476. Netherlands Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 477. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 478. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 479. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 480. Rest of Europe Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 481. MEA Guillain-Barre Syndrome Drugs Sales, by Country K Units (2025-2030)
  • Table 482. MEA Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 483. MEA Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 484. MEA Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 485. MEA Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 486. Middle East Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 487. Middle East Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 488. Middle East Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 489. Middle East Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 490. Africa Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 491. Africa Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 492. Africa Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 493. Africa Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 494. North America Guillain-Barre Syndrome Drugs Sales, by Country K Units (2025-2030)
  • Table 495. North America Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 496. North America Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 497. North America Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 498. North America Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 499. United States Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 500. United States Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 501. United States Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 502. United States Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 503. Canada Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 504. Canada Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 505. Canada Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 506. Canada Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 507. Mexico Guillain-Barre Syndrome Drugs Sales, by Type K Units (2025-2030)
  • Table 508. Mexico Guillain-Barre Syndrome Drugs Sales, by Application K Units (2025-2030)
  • Table 509. Mexico Guillain-Barre Syndrome Drugs Sales, by Forms K Units (2025-2030)
  • Table 510. Mexico Guillain-Barre Syndrome Drugs Sales, by Distribution Channel K Units (2025-2030)
  • Table 511. Research Programs/Design for This Report
  • Table 512. Key Data Information from Secondary Sources
  • Table 513. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Guillain-Barre Syndrome Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Guillain-Barre Syndrome Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Guillain-Barre Syndrome Drugs: by Forms USD Million (2018-2023)
  • Figure 7. Global Guillain-Barre Syndrome Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 9. Asia Pacific Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 10. Europe Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 11. MEA Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 12. North America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 13. Global Guillain-Barre Syndrome Drugs: by Type K Units (2018-2023)
  • Figure 14. Global Guillain-Barre Syndrome Drugs: by Application K Units (2018-2023)
  • Figure 15. Global Guillain-Barre Syndrome Drugs: by Forms K Units (2018-2023)
  • Figure 16. Global Guillain-Barre Syndrome Drugs: by Distribution Channel K Units (2018-2023)
  • Figure 17. South America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 18. Asia Pacific Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 19. Europe Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 20. MEA Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 21. North America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 22. Global Guillain-Barre Syndrome Drugs share by Players 2023 (%)
  • Figure 23. Global Guillain-Barre Syndrome Drugs share by Players (Top 3) 2023(%)
  • Figure 24. Global Guillain-Barre Syndrome Drugs share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Akari Therapeutics Plc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Akari Therapeutics Plc (United States) Revenue: by Geography 2023
  • Figure 28. Annexon Inc (United States) Revenue, Net Income and Gross profit
  • Figure 29. Annexon Inc (United States) Revenue: by Geography 2023
  • Figure 30. CuraVac Inc (United States) Revenue, Net Income and Gross profit
  • Figure 31. CuraVac Inc (United States) Revenue: by Geography 2023
  • Figure 32. Hansa Medical AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 33. Hansa Medical AB (Sweden) Revenue: by Geography 2023
  • Figure 34. Vitality Biopharma Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Vitality Biopharma Inc (United States) Revenue: by Geography 2023
  • Figure 36. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 37. Grifols, S.A. (Spain) Revenue: by Geography 2023
  • Figure 38. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 39. CSL Behring (United States) Revenue: by Geography 2023
  • Figure 40. Shire Plc (United States) Revenue, Net Income and Gross profit
  • Figure 41. Shire Plc (United States) Revenue: by Geography 2023
  • Figure 42. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. Octapharma AG (Switzerland) Revenue: by Geography 2023
  • Figure 44. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 45. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2023
  • Figure 46. Global Guillain-Barre Syndrome Drugs: by Type USD Million (2025-2030)
  • Figure 47. Global Guillain-Barre Syndrome Drugs: by Application USD Million (2025-2030)
  • Figure 48. Global Guillain-Barre Syndrome Drugs: by Forms USD Million (2025-2030)
  • Figure 49. Global Guillain-Barre Syndrome Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 50. South America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 51. Asia Pacific Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 52. Europe Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 53. MEA Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 54. North America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 55. Global Guillain-Barre Syndrome Drugs: by Type K Units (2025-2030)
  • Figure 56. Global Guillain-Barre Syndrome Drugs: by Application K Units (2025-2030)
  • Figure 57. Global Guillain-Barre Syndrome Drugs: by Forms K Units (2025-2030)
  • Figure 58. Global Guillain-Barre Syndrome Drugs: by Distribution Channel K Units (2025-2030)
  • Figure 59. South America Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 60. Asia Pacific Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 61. Europe Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 62. MEA Guillain-Barre Syndrome Drugs Share (%), by Country
  • Figure 63. North America Guillain-Barre Syndrome Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Akari Therapeutics Plc (United States)
  • Annexon Inc (United States)
  • CuraVac Inc (United States)
  • Hansa Medical AB (Sweden)
  • Vitality Biopharma Inc (United States)
  • Grifols, S.A. (Spain)
  • CSL Behring (United States)
  • Shire Plc (United States)
  • Octapharma AG (Switzerland)
  • Takeda Pharmaceuticals (Japan)
Additional players considered in the study are as follows:
China Biologic Products Holdings (China) , Biotest (Germany)
Select User Access Type

Key Highlights of Report


Jan 2025 223 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Guillain-Barre Syndrome Drugs Quantitative research analysis
Global Guillain-Barre Syndrome Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Guillain-Barre Syndrome Drugs market are Akari Therapeutics Plc (United States), Annexon Inc (United States), CuraVac Inc (United States), Hansa Medical AB (Sweden), Vitality Biopharma Inc (United States), Grifols, S.A. (Spain), CSL Behring (United States), Shire Plc (United States), Octapharma AG (Switzerland) and Takeda Pharmaceuticals (Japan), to name a few.
"Technological advancement in Guillain-Barre Syndrome Drugs" is seen as one of major influencing trends for Guillain-Barre Syndrome Drugs Market during projected period 2023-2030.
Coversin segment in Global market to hold robust market share owing to "Increasing number of patients of Guillain-Barré syndrome is driving the global Guillain-Barre Syndrome Drugs market. Nearly 6,000 patients admitted to US hospitals with a primary diagnosis of GBS every year.".

Know More About Global Guillain-Barre Syndrome Drugs Report?

Have a Query? Click Here

Other Related Reports

Burkholderia Pseudomallei Infections Drug Comprehensive Study by Type (Cholinesterase inhibitors, Memantine), Application (Reduce Fever, Improves Breathing Conditions, Others), Distribution Channel (...
$ 3650
Pharmacovigilance Software Comprehensive Study by End users (Pharma and Biotech Companies, Contract Research Organizations, Business Process Outsourcing Firms, Other), Software (Oracle Argus Safety, ...
$ 4000
Hyperpigmentation Treatment Comprehensive Study by Disease Type (Melasma, Solar lentigines, Melanoma, Precursors, Vitiligo), Distribution Channel (Beauty Stores, Drug Stores, Dermatology Clinics, Aes...
$ 3800
Digital Diabetes Management Comprehensive Study by Type (Devices, Digital Diabetes Apps, Data Management Software and Platforms), Device Type (Wearable Devices, Handheld Devices), End User (Self/Hom...
$ 3450
Perphenazine Comprehensive Study by Application (Psychosis, Antiemetic), Form (Oral, Injectable Solution), Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy, Other), End-Users...
$ 3350
Fluorouracil (5FU) Comprehensive Study by Type (Injection Product, Tablets Product, Oral Solution Product), Application (Breast Cancer, Head and Neck Cancers, Anal Cancer, Stomach Cancer, Colon Cance...
$ 3450